Amended Quarterly Report (10-q/a)
16 December 2016 - 8:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Mark One)
|
[X]
|
Quarterly Report pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934 for the Quarterly
Period Ended June 30, 2016
|
|
[ ]
|
Transition Report under Section 13 or 15(d) of the Exchange
Act
|
For the transition period from __________ to
__________
Commission file number: 333-147193
FluoroPharma Medical,
Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
20-8325616
|
|
(State or other jurisdiction of incorporation or
organization)
|
|
(I.R.S. Employer Identification No.)
|
|
8 Hillside Avenue, Suite 108
Montclair, NJ
|
|
07042
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(973) 744-1565
(Registrant’s telephone number, including area
code)
(Former name, former address and former fiscal year, if changed
since last report)
Indicate by check mark whether the registrant (1) has filed reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes [X] No [
]
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or
such shorter period that the registrant was required to submit and
post such files. Yes [X] No [
]
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
or a smaller reporting company. See the definitions of “large
accelerated filer”, “accelerated filer” and
“smaller reporting company” in Rule 12b-2 of the
Exchange Act.
|
Large accelerated filer
|
[ ]
|
|
Accelerated filer
|
[ ]
|
|
|
|
|
|
|
|
|
|
Non-accelerated filer
|
[ ]
|
|
Smaller reporting company
|
[X]
|
|
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes
[ ] No [X]
As of August 14, 2016, there were 33,756,772 shares of
$0.001 par value common stock issued and outstanding.
FORM 10-Q
FluoroPharma Medical, Inc.
|
|
|
Page
|
|
|
|
2
|
|
PART II - OTHER INFORMATION
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
4
|
This
amended quarterly report on Form 10-Q/A is being filed solely for
the purpose of notating that confidential treatment was requested
as to certain portions of Exhibit 10.1 and 10.2 in connection with
a pending application for confidential treatment. Exhibit 10.1 and
10.2 were originally filed with FluoroPharma Medical, Inc.’s
quarterly report on Form 10-Q on August 15, 2016 with certain
redactions. FluoroPharma Medical, Inc. has made no further change
to the previously filed quarterly report.
PART II - OTHER INFORMATION
Copies of the following documents are included as exhibits to this
report pursuant to Item 601 of Regulation S-K.
|
Exhibit No.
|
|
Title of Document
|
|
10.1
|
|
Amendment
to License Agreement (number A220395.01) dated as of June 1, 2016
between the Company and the General Hospital Corporation, d/b/a
Massachusetts General Hospital**
|
|
10.2
|
|
Amendment
to License Agreement (number A220396.01) dates as of June 1, 2016
between the Company and the General Hospital Corporation, d/b/a
Massachusetts General Hospital**
|
|
31.1
|
|
Certification
of the Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
31.2
|
|
Certification
of the Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
32.1
|
|
Certification
of the Chief Executive Officer pursuant to U.S.C. Section 1350 as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002***
|
|
32.2
|
|
Certification
of the Chief Financial Officer pursuant to U.S.C. Section 1350 as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002***
|
|
101.INS
|
|
XBRL
Instance Document*
|
|
101.SCH
|
|
XBRL
Schema Document*
|
|
101.CAL
|
|
XBRL
Calculation Linkbase Document*
|
|
101.LAB
|
|
XBRL
Label Linkbase Document*
|
|
101.PRE
|
|
XBRL
Presentation Linkbase Document*
|
|
101.DEF
|
|
XBRL
Definition Linkbase Document*
|
* Pursuant to Rule 406T of Regulation S-T, these interactive data
files are deemed not filed or part of a registration statement or
prospectus for purposes of Sections 11 or 12 of the Securities Act
of 1933 or Section 18 of the Securities Exchange Act of 1934 and
otherwise are not subject to liability.
** Previously filed and Confidential Treatment requested as to
certain portions of this Exhibit.
*** Previously filed.
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly
authorized.
|
|
FluoroPharma Medical, Inc.
|
|
|
|
|
|
|
Date: December 15, 2016
|
/s/ Thomas H. Tulip
|
|
|
|
Thomas H. Tulip, Ph.D.
|
|
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
|
Date: December 15, 2016
|
/s/ Tamara Rhein
|
|
|
|
Tamara Rhein
|
|
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
|
Exhibit No.
|
|
Title of Document
|
|
10.1
|
|
Amendment
to License Agreement (number A220395.01) dated as of June 1, 2016
between the Company and the General Hospital Corporation, d/b/a
Massachusetts General Hospital**
|
|
10.2
|
|
Amendment
to License Agreement (number A220396.01) dates as of June 1, 2016
between the Company and the General Hospital Corporation, d/b/a
Massachusetts General Hospital**
|
|
31.1
|
|
Certification
of the Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
31.2
|
|
Certification
of the Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
|
32.1
|
|
Certification
of the Chief Executive Officer pursuant to U.S.C. Section 1350 as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002***
|
|
32.2
|
|
Certification
of the Chief Financial Officer pursuant to U.S.C. Section 1350 as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002***
|
|
101.INS
|
|
XBRL
Instance Document*
|
|
101.SCH
|
|
XBRL
Schema Document*
|
|
101.CAL
|
|
XBRL
Calculation Linkbase Document*
|
|
101.LAB
|
|
XBRL
Label Linkbase Document*
|
|
101.PRE
|
|
XBRL
Presentation Linkbase Document*
|
|
101.DEF
|
|
XBRL
Definition Linkbase Document*
|
* Pursuant to Rule 406T of Regulation S-T, these interactive data
files are deemed not filed or part of a registration statement or
prospectus for purposes of Sections 11 or 12 of the Securities Act
of 1933 or Section 18 of the Securities Exchange Act of 1934 and
otherwise are not subject to liability.
** Previously filed and Confidential treatment requested as to
certain portions of this Exhibit
*** Previously filed
FluoroPharma Medical (CE) (USOTC:FPMI)
Historical Stock Chart
From Nov 2024 to Dec 2024
FluoroPharma Medical (CE) (USOTC:FPMI)
Historical Stock Chart
From Dec 2023 to Dec 2024
